A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy

Type of Cancer
Lung

Site
Hackensack

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-039

To Learn More Call
201-510-0910